- Schisantherin A
-
- $50.00 / 1mL
-
2024-11-19
- CAS:58546-56-8
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
- Schisantherin A
-
- $0.00 / 20mg
-
2023-02-24
- CAS:58546-56-8
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Schisantherin A
-
- $0.00 / 20mg
-
2023-02-24
- CAS:58546-56-8
- Min. Order: 5mg
- Purity: Analytical Standard
- Supply Ability: 10 g
|
| | Schisantherin A Basic information |
| Product Name: | Schisantherin A | | Synonyms: | SCHISANTHERIN A 98.0% BY HPLC;Gomisin C(Schisantherin A);Schisantherin A;SCHISANTHERINGOMISIN;(5S,6S,7S,13aS)-5,6,7,8-Tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f];Benzo[3,4]cycloocta[1,2-f][1,3]benzodioxole-5,6-diol, 5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, 5-benzoate, (5S,6S,7S,13aS)-;Gomisin, 98%, from Schisandra chinensis;Schisantherin A (Gomisin-C | | CAS: | 58546-56-8 | | MF: | C30H32O9 | | MW: | 536.57 | | EINECS: | | | Product Categories: | Inhibitors;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Heterocycles | | Mol File: | 58546-56-8.mol |  |
| | Schisantherin A Chemical Properties |
| Melting point | 110～112℃ | | Boiling point | 675.6±55.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Chloroform (Slightly), Methanol (Slightly, Sonicated) | | form | Solid | | pka | 13.70±0.60(Predicted) | | color | White to Off-White | | Water Solubility | insoluble in water |
| Safety Statements | 24/25 | | HS Code | 29329990 |
| | Schisantherin A Usage And Synthesis |
| Uses | Schisantherin A?is a ligand from Schisandra chinensis. It is capable of?suppressing interleukin-1β-induced inflammation in human chondrocytes by inhibiting NF-κB and MAPKs activation. | | Definition | ChEBI: Schisantherin A is a tannin. | | in vivo | Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to possess varied beneficial pharmacological effects. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6 and IL-1β in the BALF. In addition, the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS are suppressed by Schisantherin A. The lung wet/dry weight ratio is evaluated at 7 h after the intranasal instillation of LPS. The results show that there are no differences between control group and Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to those in the LPS group[1]. | | target | ROS | NO | NOS | MAPK | PI3K | GSK-3 | IL Receptor | PGE | TNF-α | COX | ERK | p38MAPK | JNK | NF-kB | Beta Amyloid | Akt | | IC 50 | p65 |
| | Schisantherin A Preparation Products And Raw materials |
|